SERUM IMMUNOGLOBULIN LEVELS AND INFECTION RISK IN PHASE 3 OFATUMUMAB TRIALS IN RELAPSING MULTIPLE SCLEROSIS

Authors
Category Primary study
JournalJournal of Neurology, Neurosurgery and Psychiatry
Year 2022
This article has no abstract
Epistemonikos ID: cfc7ebc3a883771c9ccc35907ac1553c8cb8b37c
First added on: Feb 14, 2025